Cargando…
Lenvatininb as Treatment for Naïve Patients with Aggressive Thyroid Cancer Bone Metastases and Bad Performance Status
Lenvatinib is an oral multityrosine kinase inhibitor (TKI) with proven effectiveness in the treatment of radioactive iodine- (RAI-) refractory and/or unresectable differentiated thyroid carcinoma (DTC). The present study reports the case of a 41-year-old male who underwent hemithyroidectomy in June...
Autores principales: | Garcia-Rodriguez, Sonia, Pinillos, Guillermo Martinez, Chaves-Conde, Manuel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292976/ https://www.ncbi.nlm.nih.gov/pubmed/32566339 http://dx.doi.org/10.1155/2020/8679149 |
Ejemplares similares
-
Bone metastases from differentiated thyroid cancer: characteristics and prognostic factors in a multicenter series
por: Piñar-Gutiérrez, Ana, et al.
Publicado: (2023) -
Aggression—Good or Bad?
por: Ratcliffe, T. A.
Publicado: (1962) -
Renal Cell Carcinoma with bone metastases isn’t always bad
por: Ruatta, Fiorella, et al.
Publicado: (2019) -
Thyroid Metastases in Bone
por: Cruickshank, M. M.
Publicado: (1938) -
Bone metastases in thyroid cancer
por: Iñiguez-Ariza, Nicole M., et al.
Publicado: (2020)